Research ArticleClinical
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
Kimiteru Ito, Rebecca Teng, Heiko Schöder, John L. Humm, Ai Ni, Laure Michaud, Reiko Nakajima, Rikiya Yamashita, Jedd D. Wolchok and Wolfgang A. Weber
Journal of Nuclear Medicine March 2019, 60 (3) 335-341; DOI: https://doi.org/10.2967/jnumed.118.213652
Kimiteru Ito
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Rebecca Teng
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Heiko Schöder
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
John L. Humm
2Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
Ai Ni
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
Laure Michaud
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Reiko Nakajima
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Rikiya Yamashita
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Jedd D. Wolchok
4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
5Department of Medicine, Weill Cornell Medicine, New York, New York; and
6Parker Institute for Cancer Immunotherapy, San Francisco, California
Wolfgang A. Weber
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 3
March 1, 2019
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
Kimiteru Ito, Rebecca Teng, Heiko Schöder, John L. Humm, Ai Ni, Laure Michaud, Reiko Nakajima, Rikiya Yamashita, Jedd D. Wolchok, Wolfgang A. Weber
Journal of Nuclear Medicine Mar 2019, 60 (3) 335-341; DOI: 10.2967/jnumed.118.213652
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
Kimiteru Ito, Rebecca Teng, Heiko Schöder, John L. Humm, Ai Ni, Laure Michaud, Reiko Nakajima, Rikiya Yamashita, Jedd D. Wolchok, Wolfgang A. Weber
Journal of Nuclear Medicine Mar 2019, 60 (3) 335-341; DOI: 10.2967/jnumed.118.213652
Jump to section
Related Articles
Cited By...
- Imaging endpoints for clinical trial use: a RECIST perspective
- Molecular imaging to support cancer immunotherapy
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
- Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy
- Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18F-FDG PET/CT